The impact of p53 mutation on tumor immune evasion: mechanistic insights and clinical implications - PubMed
4 hours ago
- #cancer therapy
- #immune evasion
- #p53 mutation
- Mutant p53 (Mtp53) loses tumor-suppressive functions and gains oncogenic properties, reshaping the tumor immune microenvironment.
- Mtp53 promotes immune evasion through mechanisms like chronic inflammation, immune cell dysfunction, and metabolic dysregulation.
- A 'metabolism-epigenetics-immunity' axis is proposed, linking Mtp53-driven metabolic changes to immune gene expression.
- The impact of Mtp53 varies by cancer type, enhancing immunogenicity in some (e.g., NSCLC) but promoting T-cell exhaustion in others (e.g., triple-negative breast cancer).
- Therapeutic strategies include Mtp53 reactivators, degraders, and neoantigen vaccines, with mixed clinical trial results.
- A multidimensional biomarker platform is needed for precise stratification and personalized treatment in Mtp53-driven cancers.